aibioCue Biopharma sets 1-for-30 reverse stock split for April 23, 2026
Tickers CUE
Cue Biopharma's 1-for-30 reverse split takes effect at 5:00 p.m. Eastern Time on April 23, 2026. The company says it is meant to restore compliance with Nasdaq's minimum bid price, and its filing still carries a going-concern determination.
Key facts
- Company
- Cue Biopharma, Inc. (NASDAQ: CUE)
- News type
- Listings
- Primary source
- Cue Biopharma, Inc. 8-K (2026-04-22)
Cue Biopharma, Inc. (Nasdaq: CUE) said in a Form 8-K filed April 22, 2026 that it had filed a certificate of amendment that day to carry out a 1-for-30 reverse stock split of its common stock. The split takes effect at 5:00 p.m. Eastern Time on April 23, 2026. Trading on the post-split basis is expected to begin at the market open on April 24, 2026, under the existing symbol CUE and a new CUSIP number, 22978P205.
Every thirty shares of issued and outstanding common stock will be combined into one share. No fractional shares will be issued, and holders who would otherwise receive one will be paid in cash instead. The 8-K says the number of authorized shares and the par value will not change. Options and warrants will be adjusted proportionately, so the number of shares each one covers falls and its exercise price rises by the same proportion. The shares available for future grants under the equity plans will be reduced in the same way.
The company says the split is intended, among other things, to bring it into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The 8-K refers back to the proxy statement for the annual meeting held on April 13, 2026. The filing is signed by Lucinda Warren, interim president and chief executive officer.
A going-concern warning
The filing's list of risks includes the company's ability to remediate its current going-concern determination, which says it does not have sufficient capital on hand to continue operations beyond the next twelve months. The same list names the company's limited cash, its history of losses, its ability to achieve profitability and its ability to obtain adequate financing. It also names the ability to maintain its collaboration with ImmunoScape.
The 8-K does not describe a financing, a new partnership or any other step aimed at the cash position. The split changes the share count and the price per share, but it does not change the amount of cash the company has on hand.
The business and the annual figures
The annual report filed March 16, 2026 describes Cue as a clinical-stage biopharmaceutical company developing injectable therapeutics for autoimmune and inflammatory diseases through its Immuno-STAT platform. The lead candidate, CUE-401, is described as a preclinical, bifunctional fusion protein designed to promote immune tolerance. The report says CUE-501, for autoimmune B cell depletion, is licensed to Boehringer Ingelheim International GmbH. CUE-101 and CUE-102 are licensed to ImmunoScape Pte. Ltd. for oncology indications.
The same annual report shows revenue of $27.5 million for 2025, against $9.3 million for 2024. The net loss was $26.6 million in 2025, against $40.7 million in 2024. Research and development expense was $37.7 million in 2025, up from $36.3 million. Cash used in operations was $21.7 million in 2025, against $36.3 million in 2024, and cash and cash equivalents were $22.5 million at the end of 2024.
What the filing does not say
The 8-K gives no closing price for the stock before the split, and it does not say when the company expects to regain compliance with the bid price requirement. It also does not give a cash balance for the end of 2025. The company's lead candidate is preclinical, and its own filing carries a going-concern determination.